Company news

Context Therapeutics Inc. news in 2024

Context Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.

View company

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

November 5, 2024

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

October 15, 2024

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

September 22, 2024

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

September 3, 2024

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

August 6, 2024

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

July 31, 2024

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

July 9, 2024

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 7, 2024

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

May 1, 2024

Context Therapeutics Announces $100 Million Private Placement

May 1, 2024

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

March 31, 2024

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

March 20, 2024

Decks in 2024